KR20160136323A - 골수형성이상증후군 치료용 jak1 억제제 - Google Patents

골수형성이상증후군 치료용 jak1 억제제 Download PDF

Info

Publication number
KR20160136323A
KR20160136323A KR1020167026668A KR20167026668A KR20160136323A KR 20160136323 A KR20160136323 A KR 20160136323A KR 1020167026668 A KR1020167026668 A KR 1020167026668A KR 20167026668 A KR20167026668 A KR 20167026668A KR 20160136323 A KR20160136323 A KR 20160136323A
Authority
KR
South Korea
Prior art keywords
pyrimidin
pyrrolo
pyrazol
trifluoromethyl
acetonitrile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020167026668A
Other languages
English (en)
Korean (ko)
Inventor
크리쉬나 바디
Original Assignee
인사이트 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인사이트 코포레이션 filed Critical 인사이트 코포레이션
Publication of KR20160136323A publication Critical patent/KR20160136323A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • Y10S514/908—

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020167026668A 2014-02-28 2015-02-27 골수형성이상증후군 치료용 jak1 억제제 Ceased KR20160136323A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461946124P 2014-02-28 2014-02-28
US61/946,124 2014-02-28
PCT/US2015/017963 WO2015131031A1 (en) 2014-02-28 2015-02-27 Jak1 inhibitors for the treatment of myelodysplastic syndromes

Publications (1)

Publication Number Publication Date
KR20160136323A true KR20160136323A (ko) 2016-11-29

Family

ID=52693052

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167026668A Ceased KR20160136323A (ko) 2014-02-28 2015-02-27 골수형성이상증후군 치료용 jak1 억제제

Country Status (29)

Country Link
US (4) US20150246046A1 (enExample)
EP (1) EP3110409B1 (enExample)
JP (1) JP6576941B2 (enExample)
KR (1) KR20160136323A (enExample)
CN (2) CN106456773A (enExample)
AU (1) AU2015222913B2 (enExample)
CA (1) CA2940659C (enExample)
CL (1) CL2016002144A1 (enExample)
CR (1) CR20160449A (enExample)
CY (1) CY1120857T1 (enExample)
DK (1) DK3110409T3 (enExample)
EA (1) EA201691745A1 (enExample)
ES (1) ES2688553T3 (enExample)
HR (1) HRP20181661T1 (enExample)
HU (1) HUE041456T2 (enExample)
IL (1) IL247475B (enExample)
LT (1) LT3110409T (enExample)
MX (1) MX372939B (enExample)
MY (1) MY185392A (enExample)
PE (1) PE20161388A1 (enExample)
PL (1) PL3110409T3 (enExample)
PT (1) PT3110409T (enExample)
RS (1) RS57723B1 (enExample)
SG (2) SG10201807952PA (enExample)
SI (1) SI3110409T1 (enExample)
SM (1) SMT201800551T1 (enExample)
UA (1) UA121857C2 (enExample)
WO (1) WO2015131031A1 (enExample)
ZA (1) ZA201606610B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180069420A (ko) * 2016-12-15 2018-06-25 가톨릭대학교 산학협력단 골수형성이상 증후군 환자의 저메틸화 제제 치료 반응성 및 생존 예후 예측용 조성물

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101391900B1 (ko) 2005-12-13 2014-05-02 인사이트 코포레이션 야누스 키나아제 억제제로서의 헤테로아릴 치환된 피롤로［2,3-ｂ］피리딘 및 피롤로［2,3-ｂ］피리미딘
WO2008157208A2 (en) 2007-06-13 2008-12-24 Incyte Corporation Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
DK2432472T3 (da) 2009-05-22 2019-11-18 Incyte Holdings Corp 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octan- eller heptan-nitril som jak-inhibitorer
PH12015502575A1 (en) 2010-03-10 2017-04-24 Incyte Corp Piperidin-4-yl azetidine derivatives as jak1 inhibitors
EP3087972A1 (en) 2010-05-21 2016-11-02 Incyte Holdings Corporation Topical formulation for a jak inhibitor
CN103415515B (zh) 2010-11-19 2015-08-26 因塞特公司 作为jak抑制剂的环丁基取代的吡咯并吡啶和吡咯并嘧啶衍生物
US8691807B2 (en) 2011-06-20 2014-04-08 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
CA2888816A1 (en) 2012-11-01 2014-05-08 Incyte Corporation Tricyclic fused thiophene derivatives as jak inhibitors
EP3949953A1 (en) 2012-11-15 2022-02-09 Incyte Holdings Corporation Sustained-release dosage forms of ruxolitinib
JP6437452B2 (ja) 2013-01-14 2018-12-12 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｐｉｍキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物
LT2945939T (lt) 2013-01-15 2020-07-27 Incyte Holdings Corporation Triazolkarboksamidai ir piridinkarboksamido junginiai, naudotini kaip pim kinazės inhibitoriai
BR112015021458B1 (pt) 2013-03-06 2022-06-07 Incyte Holdings Corporation "processos e intermediários para preparar {1-{1-[3-flúor2-(trifluormetil)isonicotinoil] piperidin-4-il}-3-[4-(7hpirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]azetidin-3-il}acetonitrila, útil no tratamento de doenças relacionadas com a atividade de janus quinases
UA117830C2 (uk) 2013-05-17 2018-10-10 Інсайт Корпорейшн Похідні біпіразолу як інгібітори jak
WO2015021153A1 (en) 2013-08-07 2015-02-12 Incyte Corporation Sustained release dosage forms for a jak1 inhibitor
EP3036238A1 (en) 2013-08-23 2016-06-29 Incyte Corporation Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
NZ763326A (en) 2014-04-08 2023-04-28 Incyte Holdings Corp Treatment of b-cell malignancies by a combination jak and pi3k inhibitor
CR20160553A (es) 2014-04-30 2017-04-25 Incyte Corp Procesos para preparar un inhibidor de jak1 y nuevas formas de este
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
CN109072190A (zh) * 2016-03-09 2018-12-21 蔚山大学校产学协力团 将jak1抑制剂作为有效成分包含的用于干细胞的增殖、分化促进或老化抑制的组成物
AU2018209579B2 (en) 2017-01-23 2020-12-24 Shanghai Longwood Biopharmaceuticals Co., Ltd. JAK kinase inhibitor and preparation method and use thereof
CN109867676B (zh) * 2017-12-01 2020-10-30 北京普祺医药科技有限公司 一种吡咯并嘧啶衍生的化合物、药物组合物以及其用途
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法
DK3746429T3 (da) 2018-01-30 2022-05-02 Incyte Corp Fremgangsmåder til fremstilling af (1-(3-fluor-2-(trifluormethyl)isonicotinyl)piperidin-4-on)
WO2019152875A1 (en) 2018-02-01 2019-08-08 Shifamed Holdings, Llc Intravascular blood pumps and methods of use and manufacture
BR122023022189A2 (pt) * 2018-02-16 2024-02-20 Incyte Corporation Usos de inibidores da via de jak1 para o tratamento de distúrbios relacionados a citocinas
CN112423759A (zh) 2018-03-30 2021-02-26 因赛特公司 使用jak抑制剂治疗化脓性汗腺炎
EP3775284A1 (en) 2018-03-30 2021-02-17 Incyte Corporation Biomarkers for inflammatory skin disease
MX2020010815A (es) 2018-04-13 2020-12-11 Incyte Corp Biomarcadores para enfermedad de injerto contra hospedero.
PE20211208A1 (es) 2018-06-01 2021-07-05 Incyte Corp Regimen de dosificacion para el tratamiento de trastornos relacionados con pi3k
EA202191170A1 (ru) 2018-10-31 2021-07-27 Инсайт Корпорейшн Комбинированная терапия для лечения гематологических заболеваний
CN111320633B (zh) * 2018-12-14 2022-09-27 中国医药研究开发中心有限公司 吡咯/咪唑并六元杂芳环类化合物及其制备方法和医药用途
MA55201A (fr) * 2019-03-05 2022-01-12 Incyte Corp Inhibiteurs de la voie jak1 pour le traitement d'un dysfonctionnement chronique de l'allogreffe pulmonaire
KR20220088699A (ko) 2019-09-27 2022-06-28 디스크 메디슨, 인크. 골수섬유증 및 관련 상태의 치료 방법
JP2022551649A (ja) 2019-10-10 2022-12-12 インサイト・コーポレイション 移植片対宿主病のバイオマーカー
US12360120B2 (en) 2019-10-10 2025-07-15 Incyte Corporation Biomarkers for graft-versus-host disease
US11992490B2 (en) 2019-10-16 2024-05-28 Incyte Corporation Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
CN111358791A (zh) * 2020-03-13 2020-07-03 深圳百奥捷生物科技有限公司 Jak/stat信号通路磷酸盐抑制剂在制备治疗dba疾病的药物中的应用
IL298118B1 (en) 2020-06-02 2025-10-01 Incyte Corp Processes for preparing JAK1 inhibitor
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
WO2022125670A1 (en) 2020-12-08 2022-06-16 Incyte Corporation Jak1 pathway inhibitors for the treatment of vitiligo
JP2024503372A (ja) * 2021-01-18 2024-01-25 アクティブ バイオテック エイビー 骨髄異形成症候群の処置における使用のためのタスキニモドまたはその薬学的に許容される塩
DK4333840T3 (da) 2021-05-03 2025-11-24 Incyte Corp Jak1-vejinhibitorer til behandling af prurigo nodularis
TW202509019A (zh) * 2023-04-27 2025-03-01 香港商維泰瑞隆（香港）生物科技有限公司 Sarm1調節子、其製劑及用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
EP1107964B8 (en) 1998-08-11 2010-04-07 Novartis AG Isoquinoline derivatives with angiogenesis inhibiting activity
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
EP1294358B1 (en) 2000-06-28 2004-08-18 Smithkline Beecham Plc Wet milling process
WO2003024967A2 (en) 2001-09-19 2003-03-27 Aventis Pharma S.A. Indolizines as kinase protein inhibitors
EP1441737B1 (en) 2001-10-30 2006-08-09 Novartis AG Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
AR042052A1 (es) 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
PE20050952A1 (es) 2003-09-24 2005-12-19 Novartis Ag Derivados de isoquinolina como inhibidores de b-raf
KR20070085433A (ko) 2004-11-24 2007-08-27 노파르티스 아게 Ｊａｋ 저해제들과 ｂｃｒ-ａｂｌ, ｆｌｔ-3, ｆａｋ 또는ｒａｆ 키나제 저해제들 중 하나 이상의 조합물
WO2006067445A2 (en) 2004-12-22 2006-06-29 Astrazeneca Ab Csf-1r kinase inhibitors
KR101391900B1 (ko) 2005-12-13 2014-05-02 인사이트 코포레이션 야누스 키나아제 억제제로서의 헤테로아릴 치환된 피롤로［2,3-ｂ］피리딘 및 피롤로［2,3-ｂ］피리미딘
MX2010010012A (es) 2008-03-11 2010-10-20 Incyte Corp Derivados de azetidina y ciclobutano como inhibidores de jak.
TW201100429A (en) 2009-05-22 2011-01-01 Incyte Corp N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
PH12015502575A1 (en) * 2010-03-10 2017-04-24 Incyte Corp Piperidin-4-yl azetidine derivatives as jak1 inhibitors
CA2818545C (en) 2010-11-19 2019-04-16 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
CN103415515B (zh) 2010-11-19 2015-08-26 因塞特公司 作为jak抑制剂的环丁基取代的吡咯并吡啶和吡咯并嘧啶衍生物
US20140073643A1 (en) * 2010-12-03 2014-03-13 Ym Biosciences Australia Pty Ltd Treatment of jak2-mediated conditions
US8691807B2 (en) 2011-06-20 2014-04-08 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
US10155987B2 (en) * 2012-06-12 2018-12-18 Dana-Farber Cancer Institute, Inc. Methods of predicting resistance to JAK inhibitor therapy
CA2888816A1 (en) * 2012-11-01 2014-05-08 Incyte Corporation Tricyclic fused thiophene derivatives as jak inhibitors
UA117830C2 (uk) * 2013-05-17 2018-10-10 Інсайт Корпорейшн Похідні біпіразолу як інгібітори jak

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180069420A (ko) * 2016-12-15 2018-06-25 가톨릭대학교 산학협력단 골수형성이상 증후군 환자의 저메틸화 제제 치료 반응성 및 생존 예후 예측용 조성물

Also Published As

Publication number Publication date
PT3110409T (pt) 2018-11-07
EP3110409B1 (en) 2018-08-15
IL247475B (en) 2020-05-31
PE20161388A1 (es) 2016-12-28
SMT201800551T1 (it) 2019-01-11
BR112016019511A2 (enExample) 2017-08-15
US20220378791A1 (en) 2022-12-01
MX372939B (es) 2020-04-03
US20150246046A1 (en) 2015-09-03
CA2940659C (en) 2023-01-03
NZ724464A (en) 2021-01-29
CA2940659A1 (en) 2015-09-03
HRP20181661T1 (hr) 2018-12-14
AU2015222913A1 (en) 2016-09-29
CY1120857T1 (el) 2019-12-11
RS57723B1 (sr) 2018-12-31
US20190111058A1 (en) 2019-04-18
DK3110409T3 (en) 2018-10-22
MX2016011103A (es) 2017-02-28
MY185392A (en) 2021-05-17
CN112494652A (zh) 2021-03-16
SG11201607083VA (en) 2016-09-29
PL3110409T3 (pl) 2018-12-31
CR20160449A (es) 2016-12-20
JP6576941B2 (ja) 2019-09-18
WO2015131031A1 (en) 2015-09-03
HUE041456T2 (hu) 2019-05-28
EA201691745A1 (ru) 2016-12-30
SG10201807952PA (en) 2018-10-30
JP2017506659A (ja) 2017-03-09
AU2015222913B2 (en) 2019-12-12
EP3110409A1 (en) 2017-01-04
UA121857C2 (uk) 2020-08-10
SI3110409T1 (sl) 2018-11-30
US20210069193A1 (en) 2021-03-11
ES2688553T3 (es) 2018-11-05
CN106456773A (zh) 2017-02-22
ZA201606610B (en) 2020-08-26
LT3110409T (lt) 2019-01-25
IL247475A0 (en) 2016-11-30
BR112016019511A8 (pt) 2023-01-24
CL2016002144A1 (es) 2016-12-16

Similar Documents

Publication Publication Date Title
EP3110409B1 (en) Jak1 inhibitors for the treatment of myelodysplastic syndromes
US11214573B2 (en) Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
US9193733B2 (en) Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
CA2921568A1 (en) Survival benefit in patients with solid tumors with elevated c-reactive protein levels
CA2818542A1 (en) Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
AU2007340530A1 (en) Novel aminopyrimidine derivative as PLK1 inhibitor
EP3691642B1 (en) [1,6]naphthyridine compounds and derivatives as cdk8/cdk19 inhibitors
HK1231762A1 (en) Jak1 inhibitors for the treatment of myelodysplastic syndromes
HK1231762B (en) Jak1 inhibitors for the treatment of myelodysplastic syndromes
EA040337B1 (ru) Ингибиторы jak1 для лечения миелодиспластических синдромов
NZ724464B2 (en) Jak1 inhibitors for the treatment of myelodysplastic syndromes
BR112016019511B1 (pt) Uso de inibidores de jak1 para o tratamento de síndromes mielodisplásicas
HK40077703A (en) Piperidin-4-yl azetidine derivatives as jak1 inhibitors
HK1258929A1 (en) Piperidin-4-yl azetidine derivatives as jak1 inhibitors
HK1258929B (en) Piperidin-4-yl azetidine derivatives as jak1 inhibitors
HK1197056B (en) Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20160927

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200227

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210903

Patent event code: PE09021S01D

AMND Amendment
E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20220225

Patent event code: PE09021S02D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220701

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20220225

Comment text: Final Notice of Reason for Refusal

Patent event code: PE06011S02I

Patent event date: 20210903

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20220701

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20211103

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20221017

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20220930

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20220701

Comment text: Final Notice of Reason for Refusal

Patent event code: PX06013S02I

Patent event date: 20220225

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20211103

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20210903

X601 Decision of rejection after re-examination